Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 20,000 Class A shares of the company, with an aggregate market value of $130,000, on 08/08/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. Over the past three months, Gibson has sold a total of 230,000 shares, generating gross proceeds of $1,831,500. The upcoming sale continues a pattern of divestment by Gibson, although the detailed history of these transactions is not provided in this summary.

Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 20,000 Class A shares of the company, with an aggregate market value of $130,000, on 08/08/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. Over the past three months, Gibson has sold a total of 230,000 shares, generating gross proceeds of $1,831,500. The upcoming sale continues a pattern of divestment by Gibson, although the detailed history of these transactions is not provided in this summary.